Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | MARK3 | P27448 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213826 | 0.87 | CHEK1 (0.64) | CHEK1AURKAJAK2CHEK2CSF1R | |
| SCHEMBL6789026 | 0.84 | CHEK1 (0.79) | CHEK1AURKAJAK2CHEK2CSF1R | |
| SCHEMBL4806341 | 0.80 | CHEK1 (0.57) | CHEK1AURKAJAK2CHEK2CSF1R | |
| SCHEMBL6217279 | 0.79 | CHEK1 (0.68) | CHEK1RPS6KB1MARK3FLT3RPS6KA3 | |
| SCHEMBL6783178 | 0.77 | CHEK1 (0.70) | CHEK1AURKAJAK2CHEK2CSF1R | |
| SCHEMBL6218491 | 0.77 | CHEK1 (0.55) | CHEK1AURKAJAK2CHEK2CSF1R | |
| SCHEMBL6218486 | 0.77 | CHEK1 (0.55) | CHEK1AURKAJAK2CHEK2CSF1R | |
| SCHEMBL6783292 | 0.76 | CHEK1 (0.58) | CHEK1AURKACHEK2CSF1RMARK3 | |
| SCHEMBL4816804 | 0.76 | CHEK1 (0.58) | CHEK1AURKAJAK2CHEK2CSF1R | |
| SCHEMBL6218484 | 0.73 | CHEK1 (0.72) | CHEK1AURKAJAK2CHEK2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603885-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | claimed |
| WO-2004080973-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | CHEK1 73/4885AURKA 314/4885JAK2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.